James P. Driscoll

Lead identification of novel and selective TYK2 inhibitors

Jun Liang, Vickie Tsui, Anne van Abbema et al. · European Journal of Medicinal Chemistry · 2013 · 123 citations · Full text

Pharmacy, Chemical Biology, Chemistry +14

<i>In vitro</i>and<i>in vivo</i>pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

Mark P. Grillo, John C. L. Erve, Ryan A. Dick et al. · Xenobiotica · 2018 · 104 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation

Y.-B. Chen, James P. Driscoll, Steven L. McAfee et al. · Clinical Infectious Diseases · 2011 · 61 citations

Life Sciences, Immunology, Infectious Diseases +17

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV

Mark J. Mitton‐Fry, Steven J. Brickner, Judith C. Hamel et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 58 citations · Full text

Pharmacy, Medicinal Chemistry, Microbiology +10

A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif

Amit S. Kalgutkar, James P. Driscoll, Sabrina X. Zhao et al. · Chemical Research in Toxicology · 2007 · 51 citations

Medicine, Medicinal Chemistry, Pharmacology +14